Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03583866 · ClinicalTrials.gov registry record · Early Phase 1
Adiposity and Endothelin Receptor Function
A Early Phase 1 study of Hypertension, sponsored by Augusta University.
- Active
- Registry status
- Early Phase 1
- Development phase
- 25
- Enrollment target
- 1
- Study location
NCT03583866: Active Early Phase 1 study of Hypertension, sponsored by Augusta University.
NCT03583866 is a Early Phase 1 study of Hypertension that is active but no longer recruiting, run by Augusta University. The registered enrollment target is 25 participants, below the 3,507-participant average among 470 other Hypertension trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03583866, a Early Phase 1 study of Hypertension, is active but no longer recruiting, sponsored by Augusta University.
- ACTIVE NOT RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 25 participants
- Enrollment target
- 1
- Study location
Study Summary
Elevated levels of ET-1 have been implicated in cardiovascular disease and some forms of hypertension. Due to the strong, positive correlation between obesity and hypertension, the present study will explore the contribution of adiposity in ETB receptor function and aim to elucidate if ETB receptor dysfunction is a major contributor to hypertension in obesity.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Candesartan
Study Locations (1)
Georgia
- Georgia Prevention Institute/ Laboratory of Integrative and Exercise Physiology - Augusta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2018-05-21 |
| Est. Completion | 2026-01 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03583866
The ClinicalTrials.gov registry entry for NCT03583866 describes a study currently listed as active not recruiting, categorized as Early Phase 1. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,507-participant average among 470 other Hypertension trials with a reported enrollment target (99% lower). The listed sponsor is Augusta University, which has 106 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hypertension appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT03583866 reports 1 study location spanning 1 distinct geographic area - top geographies include Georgia.
Frequently Asked Questions
What is clinical trial NCT03583866 about?
NCT03583866 is a clinical study titled "Adiposity and Endothelin Receptor Function". Elevated levels of ET-1 have been implicated in cardiovascular disease and some forms of hypertension. Due to the strong, positive correlation between obesity and hypertension, the present study will explore the contribution of adiposity in ETB receptor function and aim to elucidate if ETB receptor ...
What is the current status of trial NCT03583866?
This trial is currently active not recruiting. It is a Early Phase 1 study. The enrollment target is 25 participants. The study started on 2018-05-21. Estimated completion is 2026-01.
What conditions does trial NCT03583866 study?
This clinical trial studies the following conditions: Hypertension.
What interventions are being tested in trial NCT03583866?
The interventions under investigation include: Placebo (DRUG), Candesartan (DRUG).
Who is sponsoring clinical trial NCT03583866?
This trial is sponsored by Augusta University, which has 106 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03583866 being conducted?
This trial has 1 study location across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Positron Emission Tomography (PET) Imaging of Cholesterol Trafficking: Clinical Evaluation of [18F]FNP-59 in Normal Human Subjects (Group 1)
RECRUITING · Early Phase 1
-
Cardiovascular Effects of Angiotensin-(1-7) in Obesity Hypertension
RECRUITING · Early Phase 1
-
Effect of Empagliflozin on Left Atrial Function in Adults at Risk for Heart Failure
RECRUITING · Early Phase 1
-
Positron Emission Tomography (PET) Imaging of Cholesterol Trafficking: Clinical Evaluation of [18F]FNP-59 in Normal Human Subjects (Groups 2, 3 & 4)
RECRUITING · Early Phase 1
-
Sympathetic Transduction in Obesity-associated Hypertension (OB-HTN)
RECRUITING · Early Phase 1
-
Reversing Glucose and Lipid-mediated Vascular Dysfunction
RECRUITING · Early Phase 1
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.